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Abstract 
Porphyrin based photosensitizers are useful agents for photodynamic therapy (PDT) and 
fluorescence imaging of cancer. Porphyrins are also excellent metal chelators forming highly 
stable metallo-complexes making them efficient delivery vehicles for radioisotopes. Here we 
investigated the possibility of incorporating 
64Cu into a porphyrin-peptide-folate (PPF) probe 
developed previously as folate receptor (FR) targeted fluorescent/PDT agent, and evaluated 
the potential of turning the resulting 
64Cu-PPF into a positron emission tomography (PET) 
probe for cancer imaging. Noninvasive PET imaging followed by radioassay evaluated the 
tumor accumulation, pharmacokinetics and biodistribution of 
64Cu-PPF. 
64Cu-PPF uptake in 
FR-positive tumors was visible on small-animal PET images with high tumor-to-muscle ratio 
(8.88 ± 3.60) observed after 24 h. Competitive blocking studies confirmed the FR-mediated 
tracer uptake by the tumor. The ease of efficient 
64Cu-radiolabeling of PPF while retaining its 
favorable biodistribution, pharmacokinetics and selective tumor uptake, provides a robust 
strategy to transform tumor-targeted porphyrin-based photosensitizers into PET imaging 
probes. 
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Introduction 
Porphyrins  represent  one  of  the  oldest,  most 
widely  studied  chemical  structures,  both  in  nature 
and in biomedical applications [1-2]. Due to their fa-
vorable photophysical properties, such as long wave-
length absorption and emission, easy derivatization, 
high singlet oxygen quantum yield and low  in vivo 
toxicity, porphyrins have found particular success for 
photodynamic  therapy  (PDT)  and  fluorescence  im-
aging of cancer [3-6]. Several thorough reviews dis-
cussing the advantages of porphyrins as photosensi-
tizers in photodynamic therapy may be found else-
where [3, 5, 7]. Additionally, porphyrins are excellent 
metal  chelators,  forming  highly  stable  metal-
lo-complexes  [8].  With  the  well-established  stable 
chelation of Cu2+ to porphyrins, the potential use of 
64Cu-porphyrin for the detection of cancer in patients 
was recognized well over half a century ago [9]. The 
radioactive  64Cu-porphyrin  is  extremely  stable  to 
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demetallation  and  was  first  used  in vivo  in  1951  to 
develop  coincident  scintillation  counters  permitting 
more accurate localization of radioisotopes [10]. De-
spite the emerging recognition of  64Cu as a suitable 
radionuclide (t1/2 = 12.7 h, +: 17.4%, E+max = 656 keV; 
-: 39%, E-max = 573 keV) in positron emitting tomog-
raphy  (PET)  imaging  [11-12],  there  have  been  few 
efforts and even less promising results to date for us-
ing 64Cu-labeled porphyrins as PET probes [13-15]. In 
large part this is due to their poor tumor targeting, as 
well as the technical limitations of earlier PET scan-
ners. The field went into hiatus until the 1980s when 
Wilson et al. attempted to detect brain tumors using 
64Cu-porphyrin with the emerging technology of PET. 
This effort failed to generate wide interest, due to the 
limited  tumor  localization  of  the  particular 
64Cu-porphyrin  and  the  poor  spatial  resolution  (8 
mm) of PET scanners at that time [13-14]. However, a 
critical result from this study was that  64Cu-labeling 
did not alter the main characteristics (biodistribution, 
pharmacokinetics,  clearance)  of  the  host  porphyrin 
molecules [13]. Although there were sporadic efforts 
subsequently  [15-16],  the  overall  common  under-
standing of  64Cu-porphyrins’ relative inability to de-
tect cancer remains unchallenged. 
 We have previously developed a folate receptor 
(FR)-targeted  optical  imaging  and  PDT  agent,  por-
phyrin-GDEVDGSGK-folate (PPF, Figure 1) [17]. PPF 
is  composed  of  three  modules:  1)  pyropheophor-
bide-α (Pyro), a near-infrared fluorescent porphyrin, 
2) folate for targeted delivery of Pyro to FR-expressing 
cancer cells, and 3) a short peptide as a pharmacoki-
netics  modifying  (PKM)  linker.  We  have  demon-
strated, both in vitro and in vivo, that the use of three 
functional  modules  significantly  improved  tumor 
uptake efficiency, pharmacokinetics and biodistribu-
tion of the porphyrin moiety itself [17]. Here we hy-
pothesize that incorporating 64Cu into the Pyro moiety 
of PPF (64Cu-PPF) will effectively switch PPF from a 
targeted fluorescent/PDT agent into a PET probe for 
cancer imaging. Porphyrins have several ideal char-
acteristics  as  64Cu  chelators:  their  aforementioned 
stable  64Cu-chelating  ability  [10]  the  clinical-
ly-validated  minimal  toxicity  of  64Cu-prophyrin  [9], 
the compatible half-lives of  64Cu and the pharmaco-
kinetics  of  porphyrin  [13-14],  and  the  fact  that 
64Cu-chelation does not alter the biodistribution of the 
host porphyrin [13, 18]. We envision that these fea-
tures of 64Cu-prophyrin, coupled with the promising 
tumor targeting ability of PPF (Supplementary Mate-
rial: Figure S1) and the high resolution and deep tis-
sue  imaging  capability  of  modern  PET  technology 
[19-21],  will  enable  64Cu-PPF  to  1)  become  a  novel 
cancer-targeted  PET  imaging  probe,  2)  facilitate  the 
development of photosensitizers via quantitative bi-
odistribution  and  pharmacokinetics  assessment,  3) 
serve as a novel means to monitor porphyrin tumor 
uptake  in  patients  receiving  PDT,  either  by 
pre-treatment  PET  scanning  or  by  administering  a 
cocktail  of  labeled  and  unlabelled  porphyrin  and, 
most importantly 4) open the door to transform a va-





Figure  1.  The  structure  design  of  the  PPF  (Pyro-PKM 
Linker-Folate, molecular weight of 1800 g/mol). Here the 
PKM linker (pharmacokinetics modifying linker) is the pep-
tide sequence, GDEVDGSGK. 
 
Experimental Section 
64Cu-Radiolabeling: In a 1.5 mL eppendorf tube, 
2 μL DMSO was added to dissolve 50 μg (~30 nmol) of 
PPF (Pyro-Peptide-Folate). 0.1 mL of 0.1 M NH4OAc 
buffer (pH = 5.5) was added and vortexed, producing 
a dark green solution. 0.10 mL of 64Cu(Acetate)2 solu-
tion (0.5 - 5.0 mCi) was then added and the reaction 
mixture was heated in a water bath at 60  oC for 20 
min. After cooling to room temperature, a sample of 
resulting solution was analyzed by radio-UPLC. 
The  radio-UPLC  method:  The  radio-UPLC 
method  used  the  AcquityTM  Waters  UPLC  system 
(Waters Corp., Milford, MA) equipped with PDA de-
tector and Bioscan radioactive detector and Acquity 
BEH C18 column (2.1 × 100 mm, 1.7 µm; Waters). The 
flow  rate  was  0.8  mL/min.  The  mobile  phase  was 




20% solvent B (acetonitrile) at 0 min, followed by a 
gradient mobile phase shifting from 20% solvent B at 
0 min to 100% solvent B at 12 min and back to 20% 
solvent B at 13-15 min. 
Purification: Purification with Sep-Pak C18 car-
tridge  was  done  according  to  the  following  proce-
dures:  1)  Attach  a  syringe  to  the  Sep-Pak  C18  car-
tridge. 2) Flush the column with 5 mL of ethanol and 
flush the column with 10 mL of saline to equilibrate 
the column. 3) Load the sample onto the column and 
wash the sample with 10 mL of saline. 4) Elute with 
400 μl of 80% ethanol, collect the fractions of purified 
sample. 5) Dry  samples using a speed-vacuum and 
resuspend in saline. A certain amount of radioactive is 
washed down in step 3 if unlabeled free  64Cu is ob-
served  in  the  system.  With  the  natural  dark  green 
color  of  Pyro,  the  elution  of  Pyro-conjugate  can  be 
easily and directly monitored visually in step 4, and 
the fractions with the deepest color contain the high-
est  concentration  of  labeled  and  unlabeled  Py-
ro-conjugate. 
Dose Preparation:  64Cu-PPF was prepared and 
administered  without  any  further  purification.  The 
dose solution was prepared by dissolving the radio-
tracer in saline to a concentration of 2.5 - 5.0 mCi/mL 
for MicroPET imaging, and diluted to a concentration 
of 0.1 - 0.5 mCi/mL. The resulting solution was fil-
tered with a 0.20 μMillex-LG filter before being ad-
ministered to the animals. Each tumor-bearing mouse 
was injected via the tail vein with 0.1 - 0.2 mL of the 
filtered dose solution. 
Solution Stability: For in vitro solution stability 
studies, 64Cu-PPF was prepared and used without any 
further purification. The 64Cu-PPF was dissolved in a 
saline or serum solution (10% FBS in saline) with a 
final amount of 1 mCi/mL and left at room tempera-
ture  for  stability  measurements.  Samples  of  the  re-
sulting solution were analyzed by radio-UPLC at 0, 6, 
and 24 h post-incubation. The samples from the serum 
solution were centrifuged before UPLC injection.  
In  vivo  xenograft  model:  All  animal  studies 
were  carried  out  under  institutional  approval  (Uni-
versity  Health  Network,  Toronto,  Canada).  Adult 
athymic female nude mice were inoculated subcuta-
neously  with  1x106  of  KB  (FR-positive  human  epi-
dermal  cancer)  or  MT-1  (FR-positive  human  breast 
carcinoma) cells in 200 L of media in the left flank 
under general anesthesia with 2% isoflurane in oxy-
gen. Animals were maintained in pathogen-free con-
ditions  in  autoclaved  microisolator  cages.  After  2 
weeks, the tumors were 5-10 mm in diameter. 
MicroPET/CT Imaging. MicroPET imaging was 
performed using a MicroPET R4 rodent model scan-
ner  (Concorde  Microsystems,  Knoxville,  TN).  The 
tumor-bearing mice (n = 3) were anesthetized with 2% 
isoflurane in oxygen, and injected with ~500 μCi of 
64Cu-PPF via the tail vein, and placed near the center 
of the FOV where the highest resolution and sensitiv-
ity are obtained. A 10-min static PET image was ob-
tained at 4 h post injection and 30-45 min static PET 
images  were  acquired  at  24  h  post  injection. 
Throughout the imaging, mice were kept anesthetized 
and directly transferred to the scanner, together with 
the  supporting  bed,  without  any  movement.  CT 
scanning was carried out immediately after each PET 
imaging  session.  For  the  blocking  experiment,  a 
mouse bearing a KB xenograft was injected with 500 
μCi of 64Cu-PPF along with 500-fold excess free folic 
acid. The static PET images were then acquired with 
same parameters at 4 and 24 h post injection.  
Biodistribution Studies: Biodistribution studies 
were performed using the athymic nude mice bearing 
KB xenografts. Twenty tumor-bearing mice (25 - 30 g) 
were randomly divided into 5 groups. The 64Cu radi-
otracer (~12.5 μCi in 0.1 mL saline) was administered 
into each animal via the tail vein. Four animals were 
euthanized by with 2% isoflurane, exsanguinated, and 
opening of the thoracic cavity at 4 or 24 h post injec-
tion. Blood samples were withdrawn from the heart 
through a syringe. Organs were excised, washed with 
saline,  dried  with  absorbent  tissue,  weighed  and 
counted on a γ-counter (Perkin-Elmer Wizard-1480). 
Organs of interest included the tumor, heart, spleen, 
lungs,  liver,  kidneys,  adrenal,  stomach,  intestine, 
muscle, bone and brain. Organ uptake was calculated 
as a percentage of the injected dose per gram of tissue 
(%ID/g).  For  the  blocking  experiment,  each  animal 
was administered with ~12.5 μCi of  64Cu radiotracer 
along with more than 500-fold excess folic acid, and 
animals were sacrificed at 4 or 24 h post injection for 
biodistribution  studies.  The  organ  uptake  (%ID/g) 
was compared to that obtained in the absence of ex-
cess folic acid at the same time point. The biodistribu-
tion  data  and  target-to-background  (T/B)  ratios  are 
reported as the mean and standard deviation based 
on  results  from  three  animals  at  each  time  point. 
Comparison between two different radiotracers was 
made  using  the  two-way  ANOVA  test  (GraphPad 
Prim 5.0, San Diego, CA). The level of significance was 
set at p <0.05. 
Metabolism: Normal athymic nude mice (n = 2) 
were  used  to  evaluate  the  metabolic  stability  of 
64Cu-labeled PPF. Each mouse was injected with the 
64Cu radiotracer at a dose of ~200 μCi in 0.1 mL of 
saline via the tail vein. Urine samples were collected 
at 1.0 h post injection by manual void and mixed with 
saline solution. The mixture was centrifuged at 8,000 




filtered through a 0.20 μm Millex-LG filter unit. The 
filtrate was analyzed by radio-UPLC. 
Results 
 An  important  condition  for  receptor-targeted 
delivery of radiolabeled agents is the development of 
labeling chemistry that allows for the stable and facile 
preparation of radiolabeled biologically-active mole-
cules. The half-life of 64Cu (t1/2 = 12.7 h) provides ad-
equate time for radiolabeling chemistry and imaging 
over  24-48  h  to  accommodate  PPF  accumulation  at 
targeted sites [17]. The PKM linker enhances the water 
solubility  of  PPF  (Figure  1),  thereby  improving  its 
cancer-specificity,  since  water-soluble  porphyrins 
give assistance to increased affinity for tumor tissues 
[17-18]. PPF was easily dissolved in an aqueous solu-
tion with a small amount of DMSO (≤ 1%) and was 
radiolabeled efficiently in  0.1 M ammonium acetate 
buffer at 60C for 10-20 min (Figure 2a). The success of 
the  64Cu  labeling  was  determined  by  radio-UPLC 
(Ultra Performance Liquid Chromatography) using a 
C18 column. Using simultaneous multichannel moni-
toring of the pyro-specific UV absorbance at 410 nm 
and a radioactive signal, the incorporation of 64Cu into 
PPF was observed. As expected, no free 64Cu was de-
tected during the radiolabeling procedure, based on 
the radio-UPLC radioactive channel chromatography 
(Figure 2b). The radiolabeling yield was > 99.9% and 
the radiochemical purity of 64Cu-PPF was > 98% and 
the specific activity was 2.66 × 106 GBq/mol. Milder 
temperatures (room temperature and 37 C) were also 
evaluated but resulted in a lower radiolabeling effi-
ciency (50-80%), even after 20-30 min incubation. In 
this case, C18-cartridge purification removed all free 
64Cu  (see  details  of  method  in  Supporting  Infor-
mation)  and  PPF  was  efficiently  radiolabeled  with 
64Cu, successfully transforming the optical theranostic 




Figure 2. The radiolabeling procedure, quality control and stability of 
64Cu-PPF. a) The scheme of the 
64Cu-radiolabeling of 
Pyro-Conjugates, b) quality control of 
64Cu-labeled PPF by radio-UPLC, c) in vitro stability of 
64Cu-Pyro-Conjugates in saline 
or serum (10% FBS) solution (RCP = The radiochemical purity of 
64Cu-Pyro-Conjugates) (n = 3). 




The  stability  of  the  radio-metalloporphyrin  is 
critical  to  the  design  of  a  radiopharmaceutical.  The 
64Cu-PPF stability was separately measured in both a 
saline and serum solution (10% FBS) for 24 h (Figure 
3). These data demonstrates that the incorporation of 
64Cu  into  PPF  resulted  in  a  very  stable  metallopor-
phyrin complex. To evaluate the metabolic stability of 
the  64Cu-PPF  in  vivo,  athymic  nude  mice  weighing 
25-30 g were administered 200 μCi (100 μL) 64Cu-PPF 
intravenously (tail vein). All animal studies were car-
ried out under institutional approval (Ontario Cancer 
Institute, Toronto, Canada, AUP 2273.0). Urine sam-
ples were collected at 1 h post injection. Samples was 
centrifuged,  filtered,  and  evaluated  by  radio-UPLC. 
The UPLC chromatogram showed one intact 64Cu-PPF 
peak  (Figure  4)  indicating  good  metabolic  stability. 
Only a few chelators have been reported to have both 
high  stability  and  efficient  radiolabeling  protocols 
under mild conditions [24-26]. 
 We next evaluated the potential of 64Cu-PPF for 
PET imaging of FR expression in tumors in vivo. The 
FR-positive  KB  xenograft  mouse  model  previously 
used  for  PPF-based  optical  imaging  and  PDT  was 
used [17]. Animals weighing 25-30 g received a 500 
μCi (~18 MBq) intravenous injection of 64Cu-PPF. Cu 
toxicity  is  not  a  concern  as  the  dose  used  for  PET 
studies  (500  μCi,  ~18  MBq)  is  far  lower  than  those 
used for radiotherapy studies in which a 10 mCi (~370 
MBq) of 64Cu has been administered in murine models 
with  no  overt  toxicity  reported  [27-29].  MicroPET 
imaging and MicroCT scans were performed accord-
ingly at 4 and 24 h post-injection. The favorable tu-
mor-to-background  ratio  of  64Cu-PPF  is  evident  in 
Figure 5a. 64Cu-PPF easily delineates the tumor from 
all other  tissues by PET. Inhibition imaging  studies 
were conducted by co-injection of the radiotracer with 
500-fold excess folic acid. Figure 3b demonstrates that 
the uptake of 64Cu-PPF at the tumor site was signifi-
cantly  blocked  by  excess  folic  acid,  indicating  that 
64Cu-PPF  targeting  is  FR-mediated.  Biodistribution 
studies of  64Cu-PPF in the KB xenograft models at 4 
and 24 h post-injection were also performed. All vital 
organs  (including  heart,  liver,  spleen,  kidney,  lung, 
stomach,  large-intestine,  small  intestine,  adrenal, 
brain, muscle and bone) and tumors were removed, 
washed with normal saline and weighed for radioas-
say.  The  highest  uptake  was  in  the  kidneys,  corre-
sponding to the PET imaging results. Tumor uptake 
was 3.02 ± 0.55 % injected dose (ID)/g at 4 h and 1.64 
± 0.33 %ID/g at 24 h post injection (Figure 5c).  
 
 
Figure 3. The in vitro stability of 
64Cu-pyropheophorbide-a conjugates in saline (a) and serum (10% FBS) (b) was measured 
by radio-UPLC with UV 410 nm channel and radioactivity channel. We demonstrate the stability of 
64Cu chelation within the 
porphyrin, pyropheophorbide-a. Folic acid conjugation does not affect the stability of 
64Cu chelation as both 
64Cu-PPF (major 
peak, with folate) and 
64Cu-PP (minor peak, no folate) show that 
64Cu complexes stably to the porphyrin as no free 
64Cu is 





Figure 4. The metabolic stability of 
64Cu-PPF in urine was measured by radio-UPLC with UV 410 nm channel and radio-
activity channel at 1 h post injection. 
 
 
Figure 5. MicroPET/CT imaging and biodistribution. a) Representative MicroPET/CT images (coronal images (top) and 
single transverse slices passing through the tumors (bottom)) of KB tumor-bearing mice (n = 3) at 4, 24 h after intravenous 
injection of 
64Cu-PPF. b) Images, including coronal images (top) and single transverse slices passing through the tumors 
(bottom), obtained with pre-injection (0.5 h earlier) of 500-fold excess folic acid for blockade (n = 1). c) Tissue uptake of 
64Cu-PPF in selected organs at 4 h (red bars) and 24 h (blue bars) after intravenous injection. d) Ratios of tumor-to-selected 
organs in mice administered with 
64Cu-PPF at 4 h (red bars) and 24 h (blue bars) post injection. Data are presented as means 




However, the tumor-to-muscle ratio of 64Cu-PPF 
was 3.47 ± 0.47 at 4 h and 8.88 ± 3.60 at 24 h post in-
jection (Figure 5d), demonstrating the fast clearance of 
64Cu-PPF in non-target tissues while  64Cu-PPF is re-
tained within the tumor. Previous studies evaluating 
the biodistribution of 64Cu-labelled hematoporphyrin 
derivatives demonstrated no higher than a 1.07  0.25 
%ID/g [14]. Blocking biodistribution studies further 
demonstrated the FR-specific uptake (Supplementary 
Material:  Figure  S2).  Additional  experiments  with 
another FR-positive tumors confirmed these current 
findings (MicroPET imaging results of MT-1, a human 
breast  cancer  model,  are  shown  in  Supplementary 
Material: Figure S3). 
Conclusions 
 Through the present study, we hope to revitalize 
this  field  of  radio-metalloporphyrin,  based  on  the 
demonstration of 64Cu-PPF as a targeted PET imaging 
probe  for  FR-positive  tumors.  We  have  shown  the 
ease  and  efficient  radiolabeling  of  PPF  with  64Cu, 
while  retaining  its  favorable  biodistribution,  phar-
macokinetics and selective tumor uptake, characteris-
tics that were first demonstrated optically. Clearly, the 
12.7 h half-life of  64Cu is compatible with the phar-
macokinetics  of  PPF,  providing  adequate  time  for 
both the radiolabeling chemistry and accumulation of 
64Cu-PPF  at  tumor  sites.  Lastly,  we  report  the  first 
stable  chelation  of  64Cu  with  a  chlorophyll  moiety, 
pyro.  Not  only  is  64Cu-PPF  a  promising  diagnostic 
tool for FR-positive tumors, the use of 64Cu-PPF may 
be  employed  for  prediction  and  quantitative  meas-
urements of photosensitizer accumulation in tumors 
to aid in treatment planning and monitoring of PDT 
treatments. Radiolabeling PPF also provides a more 
accurate and quantitative measurement of the probe’s 
in vivo biodistribution, due to the difficulty of absolute 
quantification  of  fluorescence  in vivo.  The  ease  and 
stable chelation of 64Cu warrants further investigation 
of other radioisotopes more suitable for clinical PET 
imaging  studies  that  may  also  form  highly  stable 
metalloporphyrin  complexes  such  as  60Cu  and  62Cu 
[30]. With the multifunctional properties of porphy-
rins and the efficient and stable incorporation of 64Cu, 
this approach of first developing a porphyrin-based 
optical theranostic probe with excellent in vivo tumor 
targeting characteristics and then switching it a tar-
geted nuclear imaging probe through chelation of a 
radioisotope  can  be  translated  to  any  targeted  por-
phyrin-based agent. 
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